Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Operating Officer | September 18, 2024 | September 19, 2024 |
| bluebird bio, Inc.BLUE · Entity 78923 | Chief Operating Officer | December 06, 2018 | December 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date September 18, 2024 · Filed September 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,636 |
Last balance in matching sequence
After 2024-09-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-09-18 · Sale · Disposed 4,340 · Balance 136,272 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.09 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 114,453 unvested RSUs. Row 2 · 2024-09-18 · Sale · Disposed 4,636 · Balance 131,636 F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.09 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 114,453 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.09 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F3: Includes 114,453 unvested RSUs.
F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
bluebird bio, Inc.
Report date December 06, 2018 · Filed December 21, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,625 |
Reported balance
After 2018-12-06 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-12-06 · Exercise / conversion · Acquired 15 · Balance 15,625 F1: This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018. F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. |
| Common StockSEC Table I · non-derivative | Direct | 15,150 |
Reported balance
After 2018-12-06 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2018-12-06 · Sale · Disposed 475 · Balance 15,150 F3: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F4: The range in prices for the transaction reported on this line was $104.01 to $104.29. The average weighted price was $104.1333. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. |
| Common StockSEC Table I · non-derivative | Direct | 14,050 |
Reported balance
After 2018-12-06 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2018-12-06 · Sale · Disposed 1,100 · Balance 14,050 F3: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F5: The range in prices for the transaction reported on this line was $105.50 to $106.49. The average weighted price was $106.1123. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. |
| Common StockSEC Table I · non-derivative | Direct | 13,750 |
Reported balance
After 2018-12-06 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2018-12-06 · Sale · Disposed 300 · Balance 13,750 F3: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F6: The range in prices for the transaction reported on this line was $106.51 to $107.42. The average weighted price was $106.7042. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.65 · Expires 2026-12-01 | Direct | 40,647 |
Reported balance
After 2018-12-06 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2018-12-06 · Exercise / conversion · Disposed 15 · Balance 40,647 F1: This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018. F7: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018.
F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned.
F3: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017.
F4: The range in prices for the transaction reported on this line was $104.01 to $104.29. The average weighted price was $104.1333. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The range in prices for the transaction reported on this line was $105.50 to $106.49. The average weighted price was $106.1123. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The range in prices for the transaction reported on this line was $106.51 to $107.42. The average weighted price was $106.7042. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 14, 2021 21:21 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 40,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069423 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,768 F1 · shares: Consists of shares of Common Stock issuable under 40,315 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022. F2 · balance_after: Includes 67,243 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 14:50 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,451 | $17.22 | $42,206.22 |
DisclosureSEC source: 0001209191-21-057527 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,453 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $17.17 to $17.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 26,928 unvested RSUs. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 21:16 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 35,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025742 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,904 F1 · shares: Consists of shares of Common Stock issuable under 35,904 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:16 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 111,405 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025742 · doc4.xml · derivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,405 Underlying: Common Stock · 111,405 shares Expires 2030-09-15 F2 · derivative.exercise_date: This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 16:11 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 300 | $106.70 | $32,011.26 |
DisclosureSEC source: 0001209191-18-061735 · doc4.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,735 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F4 · price: The range in prices for the transaction reported on this line was $106.51 to $107.42. The average weighted price was $106.7042. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 16:11 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,100 | $106.11 | $116,723.53 |
DisclosureSEC source: 0001209191-18-061735 · doc4.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,035 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F3 · price: The range in prices for the transaction reported on this line was $105.50 to $106.49. The average weighted price was $106.1123. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 16:11 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 475 | $104.13 | $49,463.32 |
DisclosureSEC source: 0001209191-18-061735 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,135 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F2 · price: The range in prices for the transaction reported on this line was $104.01 to $104.29. The average weighted price was $104.1333. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2018 Filed Dec 21, 2018 16:11 UTC Amendment | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 15 | $0.00 Strike: $68.65 | $0.00 |
DisclosureSEC source: 0001209191-18-063896 · doc4a.xml · derivative · entry 5 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,647 Underlying: Common Stock · 15 shares Expires 2026-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018. F7 · derivative.exercise_date: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| December 06, 2018 Filed Dec 21, 2018 16:11 UTC Amendment | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 300 | $106.70 | $32,011.26 |
DisclosureSEC source: 0001209191-18-063896 · doc4a.xml · nonDerivative · entry 4 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 F3 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F6 · price: The range in prices for the transaction reported on this line was $106.51 to $107.42. The average weighted price was $106.7042. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. Read SEC document |
| December 06, 2018 Filed Dec 21, 2018 16:11 UTC Amendment | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,100 | $106.11 | $116,723.53 |
DisclosureSEC source: 0001209191-18-063896 · doc4a.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,050 F3 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F5 · price: The range in prices for the transaction reported on this line was $105.50 to $106.49. The average weighted price was $106.1123. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. Read SEC document |
| December 06, 2018 Filed Dec 21, 2018 16:11 UTC Amendment | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 475 | $104.13 | $49,463.32 |
DisclosureSEC source: 0001209191-18-063896 · doc4a.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,150 F3 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F4 · price: The range in prices for the transaction reported on this line was $104.01 to $104.29. The average weighted price was $104.1333. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. Read SEC document |
| December 06, 2018 Filed Dec 21, 2018 16:11 UTC Amendment | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 15 | $68.65 | $1,029.75 |
DisclosureSEC source: 0001209191-18-063896 · doc4a.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018. F2 · balance_after: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:14 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,890 | $113.83 | $215,135.30 |
DisclosureSEC source: 0001209191-18-061242 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,610 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $113.60 to $114.00. The average weighted price was $113.8282. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 16:36 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $68.65 | $0.00 |
DisclosureSEC source: 0001209191-18-036072 · doc4.xml · derivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,662 Underlying: Common Stock · 3,500 shares Expires 2026-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 16:36 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,500 | $199.11 | $696,891.65 |
DisclosureSEC source: 0001209191-18-036072 · doc4.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F2 · price: The range in prices for the transaction reported on this line was $199.00 to $199.30. The average weighted price was $199.1119. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 16:36 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 3,500 | $68.65 | $240,275.00 |
DisclosureSEC source: 0001209191-18-036072 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,044 | $0.00 Strike: $68.65 | $0.00 |
DisclosureSEC source: 0001209191-18-015546 · doc4.xml · derivative · entry 4 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,162 Underlying: Common Stock · 1,044 shares Expires 2026-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 644 | $203.03 | $130,752.09 |
DisclosureSEC source: 0001209191-18-015546 · doc4.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · kind: This sales reported in the Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F3 · price: The range in prices for the transaction reported on this line was $202.90 to $203.2750. The average weighted price was $203.0312. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 400 | $202.10 | $80,840.00 |
DisclosureSEC source: 0001209191-18-015546 · doc4.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,144 F1 · kind: This sales reported in the Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F2 · price: The range in prices for the transaction reported on this line was $201.75 to $202.60. The average weighted price was $202.10. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,044 | $68.65 | $71,670.60 |
DisclosureSEC source: 0001209191-18-015546 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $205.25 | $0.00 |
DisclosureSEC source: 0001209191-18-007407 · doc4.xml · derivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-01 F2 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2019, and in 36 equal monthly installments. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007407 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 14,794 | $0.00 Strike: $68.65 | $0.00 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · derivative · entry 14 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,206 Underlying: Common Stock · 14,794 shares Expires 2026-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 82 | $203.60 | $16,695.20 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 13 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F13 · price: The range in prices for the transaction reported on this line was $203.50 to $203.70. The average weighted price was $203.60. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 204 | $202.68 | $41,346.74 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 12 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,332 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F12 · price: The range in prices for the transaction reported on this line was $202.40 to $203.00. The average weighted price was $202.6801. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 770 | $201.57 | $155,211.90 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 11 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,536 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F11 · price: The range in prices for the transaction reported on this line was $201.30 to $202.05. The average weighted price was $201.5739. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 733 | $200.88 | $147,245.92 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 10 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,306 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F10 · price: The range in prices for the transaction reported on this line was $200.20 to $201.10. The average weighted price was $200.8812. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 697 | $199.43 | $139,004.38 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 9 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,039 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F9 · price: The range in prices for the transaction reported on this line was $199.10 to $200.05. The average weighted price was $199.4324. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 490 | $198.46 | $97,247.07 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 8 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,736 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F8 · price: The range in prices for the transaction reported on this line was $198.10 to $199.00. The average weighted price was $198.4634. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,385 | $197.61 | $273,685.00 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 7 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,226 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F7 · price: The range in prices for the transaction reported on this line was $197.10 to $198.00. The average weighted price was $197.6065. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,702 | $196.63 | $334,670.90 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 6 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,611 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F6 · price: The range in prices for the transaction reported on this line was $196.10 to $197.05. The average weighted price was $196.6339. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,039 | $195.57 | $398,760.50 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 5 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,313 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F5 · price: The range in prices for the transaction reported on this line was $195.10 to $196.05. The average weighted price was $195.5667. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 4,657 | $194.65 | $906,496.69 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 4 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,352 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F4 · price: The range in prices for the transaction reported on this line was $194.10 to $195.05. The average weighted price was $194.6525. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,703 | $193.74 | $717,433.66 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,009 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F3 · price: The range in prices for the transaction reported on this line was $193.10 to $194.05. The average weighted price was $193.7439. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 800 | $192.49 | $153,994.16 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,712 F1 · kind: This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F2 · price: The range in prices for the transaction reported on this line was $192.00 to $192.95. The average weighted price was $192.4927. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 14,794 | $68.65 | $1,015,608.10 |
DisclosureSEC source: 0001209191-18-006467 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,282 | $172.15 | $220,696.30 |
DisclosureSEC source: 0001209191-17-063885 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,718 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 11/30/2017, 25% on 11/30/2018, 25% on 11/30/2019, and 25% on 11/30/2020. F2 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $68.65 | $0.00 |
DisclosureSEC source: 0001209191-16-152995 · doc4.xml · derivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2026-12-01 F2 · derivative.exercise_date: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152995 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 11/30/2017, 25% on 11/30/2018, 25% on 11/30/2019, and 25% on 11/30/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.